David Sullivan, MD, Johns Hopkins University receives a 3 year CDMRP grant entitled “A Pharmacokinetic

Patent Cooperation Treaty Application Salts and Polymorphs of Cethromycin for the Treatment of Disease PCT/US2020/062882

Clinical Trial Success Story: David Sullivan, MD, JHU-led Team Study Finds Convalescent Plasma Can Be

Patent Cooperation Treaty Application Salts and Polymorphs of Cethromycin for the Treatment of Disease is

Global Patent Group, LLC files a Patent cooperation treaty (PCT) application PCT/US20/62882 on December 2,

 AliquantumRx Inc. announces a phase III MII funding for a project entitled “Development of Cethromycin

AliquantumRx Inc. announces the filing of a provisional patent application No. 62/942,508 entitled “Salts and

AliquantumRx Inc. announces that it has attracted an initial capital investment of up to $500,000

AliquantumRx Inc. has entered into a licensing agreement with JHTV for all of their IP

Johns Hopkins Technology Ventures files for nationalization of PCT/US15/46665.

Quantum-Biosciences LLC, a start-up company formed with the mission of development and commercialization of Cethromycin/QB101

David Sullivan, MD, professor at Johns Hopkins Bloomberg School of Public Health has been awarded